Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

453 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial.
Kudo M, Ueshima K, Chiba Y, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Arai Y. Kudo M, et al. Among authors: hatano e. Liver Cancer. 2019 Nov;8(6):505-519. doi: 10.1159/000503032. Epub 2019 Oct 8. Liver Cancer. 2019. PMID: 31799207 Free PMC article.
A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
Kanai M, Hatano E, Kobayashi S, Fujiwara Y, Marubashi S, Miyamoto A, Shiomi H, Kubo S, Ikuta S, Yanagimoto H, Terajima H, Ikoma H, Sakai D, Kodama Y, Seo S, Morita S, Ajiki T, Nagano H, Ioka T. Kanai M, et al. Among authors: hatano e. Cancer Chemother Pharmacol. 2015 Feb;75(2):293-300. doi: 10.1007/s00280-014-2648-9. Epub 2014 Dec 5. Cancer Chemother Pharmacol. 2015. PMID: 25477010 Free article. Clinical Trial.
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.
Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Kaneko S, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Tsuji A, Kudo T, Shimada M, Osaki Y, Tateishi R, Sugiyama G, Abada PB, Yang L, Okusaka T, Zhu AX. Kudo M, et al. Among authors: hatano e. J Gastroenterol. 2017 Apr;52(4):494-503. doi: 10.1007/s00535-016-1247-4. Epub 2016 Aug 22. J Gastroenterol. 2017. PMID: 27549242 Clinical Trial.
Cost-effectiveness of EOB-MRI for Hepatocellular Carcinoma in Japan.
Nishie A, Goshima S, Haradome H, Hatano E, Imai Y, Kudo M, Matsuda M, Motosugi U, Saitoh S, Yoshimitsu K, Crawford B, Kruger E, Ball G, Honda H. Nishie A, et al. Among authors: hatano e. Clin Ther. 2017 Apr;39(4):738-750.e4. doi: 10.1016/j.clinthera.2017.03.006. Epub 2017 Mar 29. Clin Ther. 2017. PMID: 28363694
Multicenter, randomized, controlled trial of S-1 monotherapy versus S-1 and interferon-α combination therapy for hepatocellular carcinoma with extrahepatic metastases.
Nagano H, Obi S, Hatano E, Kaneko S, Kanai F, Omata M, Tsuji A, Itamoto T, Yamamoto K, Tanaka M, Kubo S, Hirata K, Nakamura H, Tomimaru Y, Yamanaka T, Kojima S, Monden M. Nagano H, et al. Among authors: hatano e. Hepatol Res. 2018 Aug;48(9):717-726. doi: 10.1111/hepr.13067. Epub 2018 Mar 12. Hepatol Res. 2018. PMID: 29377364
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; SILIUS study group. Kudo M, et al. Among authors: hatano e. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432. doi: 10.1016/S2468-1253(18)30078-5. Epub 2018 Apr 7. Lancet Gastroenterol Hepatol. 2018. PMID: 29631810 Clinical Trial.
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study.
Chau I, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Kudo M, Pfiffer T, Hatano E, Chung HC, Kopeckova K, Phelip JM, Brandi G, Ohkawa S, Li CP, Okusaka T, Hsu Y, Abada PB, Zhu AX. Chau I, et al. Among authors: hatano e. Br J Cancer. 2018 Jul;119(1):19-26. doi: 10.1038/s41416-018-0103-0. Epub 2018 May 29. Br J Cancer. 2018. PMID: 29808014 Free PMC article. Clinical Trial.
Surgical Outcomes of Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: A Korea-Japan Multicenter Study.
Kim DS, Kim BW, Hatano E, Hwang S, Hasegawa K, Kudo A, Ariizumi S, Kaibori M, Fukumoto T, Baba H, Kim SH, Kubo S, Kim JM, Ahn KS, Choi SB, Jeong CY, Shima Y, Nagano H, Yamasaki O, Yu HC, Han DH, Seo HI, Park IY, Yang KS, Yamamoto M, Wang HJ. Kim DS, et al. Among authors: hatano e. Ann Surg. 2020 May;271(5):913-921. doi: 10.1097/SLA.0000000000003014. Ann Surg. 2020. PMID: 30216223
453 results